These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. Kirkali Z BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188 [TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Escudier B; Osanto S; Ljungberg B; Porta C; Wagstaff J; Mulders P; Gore M; Bex A; Bellmunt J; Bracarda S; Franklin A; Honoré PH; Ravaud A; Steijn Jv; Aziz Z; Akaza H Cancer Treat Rev; 2012 Apr; 38(2):127-32. PubMed ID: 21689888 [TBL] [Abstract][Full Text] [Related]
8. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma]. Mizuno R; Oya M Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092 [TBL] [Abstract][Full Text] [Related]
9. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. Lawindy SM; Kurian T; Kim T; Mangar D; Armstrong PA; Alsina AE; Sheffield C; Sexton WJ; Spiess PE BJU Int; 2012 Oct; 110(7):926-39. PubMed ID: 22540179 [TBL] [Abstract][Full Text] [Related]
10. EORTC-GU group expert opinion on metastatic renal cell cancer. de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861 [TBL] [Abstract][Full Text] [Related]
11. Successes and limitations of targeted therapies in renal cell carcinoma. Pracht M; Berthold D Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990 [TBL] [Abstract][Full Text] [Related]
12. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. Wright I; Kapoor A Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. Carles J; Chirivella I; Climent MA; Gallardo E; González del Alba A; Maroto JP; Mellado B; García del Muro FX Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S3-9. PubMed ID: 22689342 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
16. Considerations for the design of future clinical trials in metastatic renal cell carcinoma. Escudier B; Heng DY; Smyth-Medina A; Porta C Clin Genitourin Cancer; 2014 Feb; 12(1):1-12. PubMed ID: 24220221 [TBL] [Abstract][Full Text] [Related]
17. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713 [TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]